James Paul Rickey

Chief Financial Officer

Alpine Immune Sciences, Inc.Alpine Immune Sciences, Inc.Braveheart Bio, Inc.

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 1 buy · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€434k

▼ Sales (1 ops.)

€209k

Latest filing published 07 Aug 2026 for Braveheart Bio, Inc., €434k. Read the official filing

Filing timeline

BuySale

James Paul Rickey

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

James Paul Rickey: trading record in brief

James Paul Rickey is a declared insider at 2 companies (finance chief); the most frequent names are Alpine Immune Sciences, Inc. and Braveheart Bio, Inc. Between 31 December 2021 and 7 August 2026, the trades on record add up to 11 filings.

Both buying and selling appear: 1 purchase worth €434k, against 1 sale worth €209k. The net balance comes to €225k on the buying side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 1 share grant and 7 option exercises. 2026 to date brings 1 purchase and no sales.

The newest entry dates from 7 August 2026: an open-market purchase of €434k, in Braveheart Bio, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.